PTGS2 and pachyonychia congenita: Prospective studies provide further evidence supporting the involvement of the COX-2 pathway in pancreatic carcinogenesis and suggest that urinary prostaglandin E metabolite (PGE-M) may serve as a biomarker for predicting PC risk (90).